Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ADEL K EL-NAGGAR and JEFFREY N MYERS.
ADEL K EL-NAGGAR
Connection Strength
3.989
JEFFREY N MYERS
  1. t(3;8) as the sole chromosomal abnormality in a myoepithelial carcinoma ex pleomorphic adenoma: a putative progression event. Head Neck. 2013 Jun; 35(6):E181-3.
    View in: PubMed
    Score: 0.205
  2. Loss of p53 drives neuron reprogramming in head and neck cancer. Nature. 2020 02; 578(7795):449-454.
    View in: PubMed
    Score: 0.179
  3. Editor's Note: Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer. Clin Cancer Res. 2019 08 01; 25(15):4862.
    View in: PubMed
    Score: 0.172
  4. Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients. Cancer Res. 2015 Apr 01; 75(7):1205-15.
    View in: PubMed
    Score: 0.126
  5. Squamous cell carcinoma of the oral tongue in young non-smokers is genomically similar to tumors in older smokers. Clin Cancer Res. 2014 Jul 15; 20(14):3842-8.
    View in: PubMed
    Score: 0.120
  6. Residual nodal disease in patients with advanced-stage oropharyngeal squamous cell carcinoma treated with definitive radiation therapy and posttreatment neck dissection: Association with locoregional recurrence, distant metastasis, and decreased survival. Head Neck. 2013 Oct; 35(10):1454-60.
    View in: PubMed
    Score: 0.107
  7. Early postoperative epidermal growth factor receptor inhibition: safety and effectiveness in inhibiting microscopic residual of oral squamous cell carcinoma in vivo. Head Neck. 2013 Mar; 35(3):321-8.
    View in: PubMed
    Score: 0.103
  8. Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma. Head Neck. 2011 Feb; 33(2):189-98.
    View in: PubMed
    Score: 0.096
  9. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma. Cancer. 2010 Jun 15; 116(12):2974-83.
    View in: PubMed
    Score: 0.091
  10. Sentinel lymph node biopsy accurately stages the regional lymph nodes for T1-T2 oral squamous cell carcinomas: results of a prospective multi-institutional trial. J Clin Oncol. 2010 Mar 10; 28(8):1395-400.
    View in: PubMed
    Score: 0.089
  11. TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene. 2010 Apr 08; 29(14):2047-59.
    View in: PubMed
    Score: 0.089
  12. Phosphorylated insulin like growth factor-I receptor expression and its clinico-pathological significance in histologic subtypes of human thyroid cancer. Exp Biol Med (Maywood). 2009 Apr; 234(4):372-86.
    View in: PubMed
    Score: 0.083
  13. Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model. Clin Cancer Res. 2008 Aug 15; 14(16):5081-9.
    View in: PubMed
    Score: 0.081
  14. Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer. 2008 May 01; 112(9):2088-100.
    View in: PubMed
    Score: 0.079
  15. Reciprocal negative regulation between S100A7/psoriasin and beta-catenin signaling plays an important role in tumor progression of squamous cell carcinoma of oral cavity. Oncogene. 2008 Jun 05; 27(25):3527-38.
    View in: PubMed
    Score: 0.078
  16. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther. 2007 Jun; 6(6):1785-92.
    View in: PubMed
    Score: 0.074
  17. Effects of the integrin-linked kinase inhibitor QLT0267 on squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2007 Jan; 133(1):15-23.
    View in: PubMed
    Score: 0.072
  18. Implications of methylation patterns of cancer genes in salivary gland tumors. Clin Cancer Res. 2006 Dec 15; 12(24):7353-8.
    View in: PubMed
    Score: 0.072
  19. Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model. Mol Cancer Ther. 2006 Nov; 5(11):2696-705.
    View in: PubMed
    Score: 0.071
  20. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma. Clin Cancer Res. 2006 Aug 01; 12(15):4755-65.
    View in: PubMed
    Score: 0.070
  21. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 1):3425-34.
    View in: PubMed
    Score: 0.069
  22. The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell carcinoma of the head and neck. Oral Oncol. 2006 Apr; 42(4):430-9.
    View in: PubMed
    Score: 0.068
  23. Presence of malignant tumor cells in persistent neck disease after radiotherapy for advanced squamous cell carcinoma of the oropharynx is associated with poor survival. Eur Arch Otorhinolaryngol. 2006 Apr; 263(4):313-8.
    View in: PubMed
    Score: 0.067
  24. Selective vs modified radical neck dissection and postoperative radiotherapy vs observation in the treatment of squamous cell carcinoma of the oral tongue. Arch Otolaryngol Head Neck Surg. 2005 Oct; 131(10):874-8.
    View in: PubMed
    Score: 0.066
  25. Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol Cancer Ther. 2005 Aug; 4(8):1146-56.
    View in: PubMed
    Score: 0.065
  26. Differential expression of p63 isotypes (DeltaN and TA) in salivary gland neoplasms: biological and diagnostic implications. Hum Pathol. 2005 Jul; 36(7):821-7.
    View in: PubMed
    Score: 0.065
  27. The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. Br J Cancer. 2005 May 23; 92(10):1899-905.
    View in: PubMed
    Score: 0.064
  28. ICAM-5 (telencephalin) gene expression in head and neck squamous carcinoma tumorigenesis and perineural invasion! Oral Oncol. 2005 Jul; 41(6):580-8.
    View in: PubMed
    Score: 0.064
  29. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res. 2004 Dec 15; 10(24):8594-602.
    View in: PubMed
    Score: 0.062
  30. Outcomes in patients with adenoid cystic carcinoma of the lacrimal gland. Ophthalmic Plast Reconstr Surg. 2004 Jan; 20(1):22-6.
    View in: PubMed
    Score: 0.058
  31. Disparity in pathologic and clinical lymph node staging in oral tongue carcinoma. Implication for therapeutic decision making. Cancer. 2003 Aug 01; 98(3):508-15.
    View in: PubMed
    Score: 0.057
  32. Extent of extracapsular spread: a critical prognosticator in oral tongue cancer. Cancer. 2003 Mar 15; 97(6):1464-70.
    View in: PubMed
    Score: 0.055
  33. Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort. Cancer. 2023 03 01; 129(5):714-727.
    View in: PubMed
    Score: 0.055
  34. Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Apr 14; 28(8):1735.
    View in: PubMed
    Score: 0.052
  35. Elective neck dissection versus observation in patients with head and neck cutaneous squamous cell carcinoma. Cancer. 2021 12 01; 127(23):4413-4420.
    View in: PubMed
    Score: 0.049
  36. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2021 08 15; 27(16):4557-4565.
    View in: PubMed
    Score: 0.049
  37. Epithelial Mutant p53 Promotes Resistance to Anti-PD-1-Mediated Oral Cancer Immunoprevention in Carcinogen-Induced Mouse Models. Cancers (Basel). 2021 Mar 23; 13(6).
    View in: PubMed
    Score: 0.048
  38. Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. Head Neck. 2021 05; 43(5):1592-1603.
    View in: PubMed
    Score: 0.048
  39. Integrating depth of invasion in T classification improves the prognostic performance of the American Joint Committee on Cancer primary tumor staging system for cutaneous squamous cell carcinoma of the head and neck. Eur J Cancer. 2021 02; 144:169-177.
    View in: PubMed
    Score: 0.047
  40. Inclusion of extranodal extension in the lymph node classification of cutaneous squamous cell carcinoma of the head and neck. Cancer. 2021 04 15; 127(8):1238-1245.
    View in: PubMed
    Score: 0.047
  41. Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngol Head Neck Surg. 2020 02 01; 146(2):128-135.
    View in: PubMed
    Score: 0.045
  42. Expression of p16, Rb, and cyclin D1 gene products in oral and laryngeal squamous carcinoma: biological and clinical implications. Hum Pathol. 1999 Sep; 30(9):1013-8.
    View in: PubMed
    Score: 0.043
  43. Editor's Note: Identification of Insulin-Like Growth Factor Binding Protein-3 as a Farnesyl Transferase Inhibitor SCH66336-Induced Negative Regulator of Angiogenesis in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2019 08 01; 25(15):4861.
    View in: PubMed
    Score: 0.043
  44. Genetic alterations in oral squamous cell carcinoma of young adults. Oral Oncol. 1999 May; 35(3):251-6.
    View in: PubMed
    Score: 0.042
  45. PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions. Cancer Prev Res (Phila). 2017 Dec; 10(12):684-693.
    View in: PubMed
    Score: 0.038
  46. Cdkn2a suppresses metastasis in squamous cell carcinomas induced by the gain-of-function mutant p53(R172H). J Pathol. 2016 10; 240(2):224-34.
    View in: PubMed
    Score: 0.035
  47. Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer. Clin Cancer Res. 2016 Sep 15; 22(18):4643-50.
    View in: PubMed
    Score: 0.034
  48. New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development. Cancer Prev Res (Phila). 2015 Nov; 8(11):1027-35.
    View in: PubMed
    Score: 0.033
  49. Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer. Cancer Res. 2015 Apr 01; 75(7):1527-36.
    View in: PubMed
    Score: 0.032
  50. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res. 2014 Dec 15; 20(24):6582-92.
    View in: PubMed
    Score: 0.031
  51. Comprehensive assessment of prognostic markers for sinonasal squamous cell carcinoma. Head Neck. 2014 Aug; 36(8):1094-102.
    View in: PubMed
    Score: 0.029
  52. Molecular profiling of sinonasal undifferentiated carcinoma. Head Neck. 2014 Jan; 36(1):15-21.
    View in: PubMed
    Score: 0.028
  53. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov. 2013 Jul; 3(7):770-81.
    View in: PubMed
    Score: 0.028
  54. Prediction of neck dissection requirement after definitive radiotherapy for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2012 Mar 01; 82(3):e367-74.
    View in: PubMed
    Score: 0.026
  55. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011 Aug 26; 333(6046):1154-7.
    View in: PubMed
    Score: 0.025
  56. KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma. Oncogene. 2011 Jul 14; 30(28):3163-73.
    View in: PubMed
    Score: 0.024
  57. Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am J Pathol. 2011 Feb; 178(2):548-71.
    View in: PubMed
    Score: 0.024
  58. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther. 2010 Jun; 9(6):1755-63.
    View in: PubMed
    Score: 0.023
  59. Reduced DNA repair capacity for removing tobacco carcinogen-induced DNA adducts contributes to risk of head and neck cancer but not tumor characteristics. Clin Cancer Res. 2010 Jan 15; 16(2):764-74.
    View in: PubMed
    Score: 0.022
  60. Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res (Phila). 2009 Jan; 2(1):14-21.
    View in: PubMed
    Score: 0.021
  61. An orthotopic murine model of sinonasal malignancy. Clin Cancer Res. 2008 Nov 15; 14(22):7348-57.
    View in: PubMed
    Score: 0.020
  62. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab. 2008 Jan; 93(1):278-84.
    View in: PubMed
    Score: 0.019
  63. Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma. Clin Cancer Res. 2006 Jan 15; 12(2):653-61.
    View in: PubMed
    Score: 0.017
  64. Akt activation correlates with adverse outcome in tongue cancer. Cancer. 2005 Dec 01; 104(11):2430-6.
    View in: PubMed
    Score: 0.017
  65. Proteome-wide analysis of head and neck squamous cell carcinomas using laser-capture microdissection and tandem mass spectrometry. Oral Oncol. 2005 Feb; 41(2):183-99.
    View in: PubMed
    Score: 0.016
  66. Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography. Oral Oncol. 2004 Nov; 40(10):1026-32.
    View in: PubMed
    Score: 0.015
  67. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer. 2001 Nov 01; 92(9):2364-73.
    View in: PubMed
    Score: 0.013
  68. Malignant melanoma arising within a burn scar case report and review of the literature. Ann Otol Rhinol Laryngol. 2001 Apr; 110(4):369-76.
    View in: PubMed
    Score: 0.012
  69. Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression. J Natl Cancer Inst. 2000 Jan 05; 92(1):69-73.
    View in: PubMed
    Score: 0.011
  70. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg. 1999 Oct; 125(10):1083-9.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.